• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

RISA Labs Raises $3.5M for AI-Powered Oncology Prior Authorizations Platform

by Syed Hamza Sohail 04/17/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  Cancer patients don’t just fight the disease – they fight the system. Today, life-saving treatments are routinely delayed by days or even weeks due to manual, error-prone workflows

–   To solve this, RISA Labs has raised a $3.5M funding round to help healthcare organizations eliminate one of the most persistent barriers to timely cancer care: prior authorization delays. RISA Labs has already proven that faster care is possible by dramatically reducing manual workflows and administrative burden.

RISA Secures Funding to Revolutionize Oncology Operations with AI-Driven Workflow Orchestration

RISA, a Silicon Valley-based startup founded by IIT Kanpur alumni and serial entrepreneurs Kshitij Jaggi (CEO) and Kumar Shivang (CTO), is pioneering a systems-first approach to healthcare automation. Drawing from their experience scaling Urban Health, the duo developed RISA to address the fragmented, slow, and error-prone workflows that plague today’s healthcare institutions. Their vision centers on building a foundational AI operating system that can simulate, understand, and orchestrate end-to-end institutional workflows—particularly in the oncology space.

At the core of RISA’s innovation is the Business Operating System as a Service (BOSS)—a full-stack orchestration engine purpose-built for the vertical complexity of healthcare. Unlike traditional automation bots or AI assistants, BOSS:

  • Breaks down complex workflows into micro-tasks
  • Delegates these tasks to a network of intelligent agents, including large language models (LLMs), digital twins, and reinforcement learners
  • Integrates seamlessly with the institution’s entire software stack

This architecture enables the creation of a parallel digital workforce that operates both independently and alongside human teams. For example, in a leading U.S. cancer center, BOSS reduced prior authorization times from 30 minutes to under five, processed over $1 million in medication approvals, freed up 80% of staff time, and cut administrative costs by 66%.

The platform addresses a critical pain point in oncology: prior authorizations, which remain among the least automated components of the healthcare system. According to Ben Freeberg, Managing Partner at Oncology Ventures, delays in authorization affect 70% of cancer patients, with one-third of those delays lasting a month—potentially increasing the risk of death by up to 13% in certain cancers. RISA’s solution aims to eliminate this inefficiency and the dangers it presents.

RISA’s long-term vision extends beyond prior authorizations. The company aims to become the AI transformation partner across the entire oncology ecosystem, facilitating coordination and intelligence-sharing between:

  • Providers
  • Life sciences organizations
  • Other key stakeholders in the drug development and delivery pipeline

By doing so, RISA seeks to establish a unified orchestration layer for oncology operations, reshaping both clinical and operational workflows at scale.

To accelerate deployment, RISA has raised a seed round led by Binny Bansal (co-founder of Flipkart), with participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The funding will support the expansion of RISA’s platform to 100 additional cancer centers nationwide over the next two years.

With this strategic funding and an ambitious roadmap, RISA is positioned to redefine how cancer care is delivered—digitally doubling institutional capacity and improving patient outcomes through intelligent automation.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Automated Prior Authorizations, Prior Authorization, Revenue Cycle Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |